3 completed. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Clesrovimab: new trials by email Literature Review of Clesrovimab trials Research Report on Clesrovimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) Clesrovimab, Placebo - Respiratory Syncytial Virus Infection | Phase 2 / Phase 3 | Completed | Merck Sharp & Dohme LLC | 3632 | 2021-04-07 | 2026-02-11 |
| Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005) Clesrovimab, Placebo, RSV-A Memphis 37b - Respiratory Syncytial Viruses | Phase 2 | Completed | Merck Sharp & Dohme LLC | 80 | 2019-10-28 | 2022-09-14 |
| Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) Clesrovimab, Placebo - Respiratory Tract Infection, Respiratory Syncytial Virus | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 183 | 2018-09-20 | 2025-01-14 |
Respiratory Syncytial Virus Infections (1) · Respiratory Tract Infections (1)
Chile (2) · Colombia (2) · South Africa (2) · South Korea (2) · United Kingdom (2) · United States (2) · Argentina (1) · Belgium (1) · Canada (1) · China (1) · Denmark (1) · Finland (1) · France (1) · Israel (1) · Italy (1)
PMID 34774184, PMID 34775220, PMID 39590882, PMID 39601265, PMID 40673795, PMID 40961446
2017 (1), 2018 (1)